CD274 and gastric cancer: In the cohort of toripalimab monotherapy for advanced refractory GC, mPFS (5.5 vs 1.9 months, P = 0.092) and mOS (12.1 vs 5.3 months, P = 0.45) were highly increased in PD-L1 positive patients, but the differences in survival outcomes were not statistically significant (5).